Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 18, 2013

Prosonix completes patient dosing in Phase II study of PSX1002

Prosonix has completed patient dosing and follow-up procedures in its Phase II study of PSX1002, a novel, orally inhaled, drug-only, pMDI suspension formulation of the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide.

copd

Prosonix has completed patient dosing and follow-up procedures in its Phase II study of PSX1002, a novel, orally inhaled, drug-only, pMDI suspension formulation of the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide.

The company is developing PSX1002, which was designed using Prosonix’s proprietary particle engineering technology platform, as a potential orally inhaled monotherapy for chronic obstructive pulmonary disease (COPD).

Prosonix CEO David Hipkiss said the novel formulation of glycopyrronium bromide could deliver considerable clinical benefits to COPD patients.

"In addition to the excellent progress with PSX1002, we continue to advance our development pipeline of particle-engineered mono and combination respiratory medicines, with the first filing of our lead product PSX1001 in the European Union as a directly substitutable generic inhaled corticosteroid (ICS) for asthma and COPD expected in mid-2014," Hipkiss added.

The study is designed to investigate the effects on expiratory lung function, tolerability and safety of a range of doses of orally inhaled PSX1002 compared to placebo delivered through pressurised metered dose inhaler (pMDI) in male and female patients diagnosed with moderate or severe COPD.

At the Medicines Evaluation Unit in Manchester, UK, the randomised, double-blind, single-dose study recruited 37 patients and 33 completed all five dosing sessions.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Improved lung function based on Forced Expiratory Volume in one second (FEV1) area under the curve from time zero to 24 hours post dose is the study’s primary endpoint.

The study will also assess multiple secondary physiological (lung function) and pharmacokinetic endpoints.

Top-line results of the study are expected in the first quarter 2014.


Image: A chest X-ray demonstrating severe COPD. Photo courtesy of James Heilman, MD.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU